Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization

  Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary

Business Wire

OSAKA, Japan -- March 12, 2013

Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536)
Japan's leading ophthalmic pharmaceutical company, announced today the
appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen
Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new
appointment, Dr. Shams was Vice President and Head of Global Clinical
Development and Medical Affairs (GCD&MA). Dr. Shams received his medical
degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in
Microbiology & Immunology from the University of South Carolina. After
completing a fellowship in Cornea and External Disease at the Schepens Eye
Research Institute & Department of Ophthalmology, Harvard Medical School, he
served on the Research Faculty in the Department. Dr. Shams joined Santen Inc.
almost 3 years ago. His industry experience spans 19 years across multiple
therapeutic areas and includes tenures with Genentech, Novartis Ophthamics,
Opko Health, On Demand Therapeutics and Storz Ophthalmics. While at Genentech,
Dr. Shams led the clinical team responsible for the development and approval
of Ranibizumab (Lucentis^®).

Akihiro Tsujimura, who has been President & CEO of Santen Inc. since 2010,
will become the Head of Santen’s Asia Division, including China and Korea
Business Units. Regarding the change, Akira Kurokawa, President and CEO of
Santen Ltd., noted “Under Aki’s leadership, we have made significant strides
in expanding our global drug development & business development capabilities
in the US. He was instrumental in the establishment of the Global Clinical
Development & Medical Affairs Group in the US, and under his leadership,
worldwide development of DE-109 for the treatment of non-infectious, chronic,
posterior uveitis began in 2011.”

Mr. Kurokawa noted that this change in management structure supports an
increased focus on the global development of Santen’s pipeline and the
critical role that the U.S. organization is playing in Santen’s globalization
initiative. "Dr. Shams is a highly respected scientist with expertise in
developing and commercializing ophthalmic drugs globally. His experience as a
global R&D professional should prove invaluable as we continue to grow our
business worldwide,” stated Mr. Kurokawa.

Dr. Shams commented, “The U.S. subsidiary of Santen will leverage its assets
to successfully commercialize differentiated products to meet the needs of our
patients and their ophthalmologists. We will strive to accelerate the
development of Santen’s pipeline. I look forward to working with our partners,
both internal and external, to accomplish this.”

Santen Inc., based in Emeryville, California, is the U.S. subsidiary of Santen
Pharmaceutical Co., Ltd., a billion dollar global company headquartered in
Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic
products for physicians worldwide. Among prescription ophthalmic
pharmaceuticals, Santen holds the top share within the Japanese market, is a
market leader within China, and is one of the leading ophthalmic companies
worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its
wholly-owned Emeryville, California based Santen Inc. Santen’s global product
pipeline includes many more prescription pharmaceuticals in varying clinical
trial phases. A detailed listing, as well as additional corporate information,
is available online at


Pascale Communications, LLC
Allison Potter, 814-221-2661
Santen Inc.
Mike Ford, 415-268-9058
Press spacebar to pause and continue. Press esc to stop.